Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;12:831105. doi: 10.3389/fonc.2022.831105

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Miano, Romaniello, Mazzeschi, Morselli, Da Pra, Sacchi, Bongiovanni, Sgarzi, Pantano, Lauriola and D’Uva

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

ERBB4 mRNA levels in breast cancer patients stratified for molecular subtypes and their correlation with relapse-free patients’ survival. (A–D) Relapse-free survival (RFS) of breast cancer patients stratified for ERBB4 mRNA levels (lower versus upper tercile) in molecular subtypes, namely (A) luminal A (n = 1809 patients), (B) HER2-enriched (n = 695 patients), (C) luminal B (n = 1353 patients), and (D) basal-like (n = 953 patients). Data on normal-like subgroup are not provided due to the insufficient patient number; (E) ERBB4 mRNA expression levels in breast cancer patients stratified for molecular subtypes (PAM50, n = 9,727 patients); numerical data are presented as mean (error bars show s.e.m.) and * represents the expression levels of single patients falling outside the error bars.